Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 13132Neoplasms 10477Carcinoma, Non-Small-Cell Lung 6870Prostatic Neoplasms 6268Colorectal Neoplasms 5945Lung Neoplasms 5102Multiple Myeloma 3576Pancreatic Neoplasms 3561Leukemia, Myeloid, Acute 3510Neoplasm Metastasis 3507Carcinoma, Hepatocellular 3271Ovarian Neoplasms 3168Melanoma 3139Stomach Neoplasms 3056Lymphoma 2982Head and Neck Neoplasms 2603Recurrence 2556Precursor Cell Lymphoblastic Leukemia-Lymphoma 2499Leukemia 2362Colonic Neoplasms 2327Brain Neoplasms 2310Lymphoma, Non-Hodgkin 2268Rectal Neoplasms 2191Uterine Cervical Neoplasms 2191Glioblastoma 2014Leukemia, Lymphocytic, Chronic, B-Cell 1992Carcinoma, Renal Cell 1913Squamous Cell Carcinoma of Head and Neck 1880Lymphoma, Follicular 1847Esophageal Neoplasms 1800

Interventions

vistusertib 1acalabrutinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
DLBCL × Clear all
NCT03205046 2021-01-06

A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies

Acerta Pharma BV

Phase 1/2 Terminated
25 enrolled 11 charts
Lymphoid

DLBCL

Data powered by HemOnc (CC BY 4.0) Colophon âš¡